Retinoblastom Tedavisinde Güncel Yaklaşımlar

Retinoblastoma is the most common primary intraocular malignant tumor of early childhood, and 95% of all cases are diagnosed before\udthe age of 5 years. Tumors are evaluated and classified based on laterality, genetic features, the number, location and size of foci. Currently,\udsystemic and intaarterial chemotherapy are the most commonly used management options worldwide. Group A tumors are treated with\udfocal techniques including transpupillary thermotherapy, cryotherapy, or laser photocoagulation. Groups B and C tumors are managed\udwith systemic chemotherapy and focal consolidation techniques. Group D lesions are best treated with systemic chemotherapy, subtenon\udcarboplatin injection or external beam radiotherapy. Alternatively, groups B, C and D tumors can be primarily treated with intraarterial\udchemotherapy. Intravitreal melphalan injection can be an alternative treatment for eyes with recurrent or persistent vitreous seeding.\udGroup E eyes are often enucleated, however, depending on the fellow eye, systemic or intraarterial chemotherapy may be administered.\udSystemic chemotherapy is also mandatory if high-risk histopathological features are found after enucleation. (Turk J Ophthalmol 2014;\ud44: Supplement 22-8